medicine

Cambridge, UK, 16th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has signed up for the early-stage development of a novel vaccine targeting prevention of influenza. The project signals ELC Group’s entry into the pharmaceutical development market.

The vaccine development will be overseen by a specialist R&D team at ELC Group, including regulatory vaccines experts who have worked on and regulated a number of key worldwide paediatric vaccines. The highly experience team includes a number of current advisers to the World Health Organisation.

Cambridge, UK, 9th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.

The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.

The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.

London, UK, 18th June 2014 – The Chairman and CEO of DNA Electronics, a provider of point-of-care genomic diagnostics solutions for medical and healthcare applications, Chris Toumazou, has been awarded the European Inventor Award 2014 in the Research category, for his rapid USB-based DNA testing device.

Announced at the European Inventor Awards ceremony in Berlin on June 17th 2014, Toumazou’s win recognises his contribution to medical research with his ground-breaking invention. The device, which can show the results of a DNA test within minutes, uses silicon transistors to identify DNA and RNA, offering a simpler, cheaper and more discrete alternative to existing DNA analysis equipment.

Abingdon, Oxfordshire, UK, 14th April 2014 – Isansys Lifecare Limited, the provider of complete real-time physiological patient status services and systems, today announces that it has won two SBRI (Small Business Research Initiative) Healthcare contracts. Granted as part of NHS England’s initiative to enhance the adoption of innovative devices and new technologies, the contracts have been signed with Papworth NHS Trust (Cambridge, UK) for Isansys to expand the functionality and applications of its CE-marked Patient Status Engine (PSE) in two theme areas– patient safety and cancer. Isansys is currently working with a number of hospitals and healthcare service providers to deliver patient monitoring services and patient status solutions based on the PSE platform.

Abingdon, UK, 12th November 2013. – Oxford Optronix, the leading provider of advanced
research instrumentation for the clinical medicine and life science industries, today announces the
formal launch of HypoxyLab™ – the industry’s first benchtop, HEPA-filtered,
precision-controlled hypoxia workstation. HypoxyLab creates optimal, contamination-free conditions
for a wide variety of cell-based research fields, including cancer biology, radiation cell biology,
cardiovascular research, apoptosis, neurology, stem cell research, multidisciplinary drug
development and proteomics.

HypoxyLab is a unique, fully-featured and easy-to-use hypoxia workstation that accurately reproduces
physiological conditions for cell-based research. HypoxyLab provides a highly stable, localised
environment in which levels of oxygen, carbon dioxide, temperature and humidity are precisely
controlled within a HEPA-filtered isolation work chamber.

Bristol, UK - October 10th, 2013. Research Media, who produce the International Innovation series of publications, has announced details for next year’s World Research and Innovation Congress – Pioneers in Healthcare (WRIC) taking place on 4th and 5th June in Brussels. Themed ‘How we do research – maximising impact through collaboration’, the event will address key issues such as international collaboration, funding for research and supporting research excellence.
The future of healthcare research relies on innovation and collaboration. The event will attract a worldwide audience of scientific healthcare representatives who will benefit from a dynamic programme comprising presentations, workshops and interactive panel sessions.
The event will provide delegates with the opportunity to discuss the latest issues and developments in healthcare, hear about funding opportunities, share knowledge, network and form partnerships.